Equities research analysts at FBR & Co began coverage on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a research report issued on Thursday, Marketbeat reports. The brokerage set a “buy” rating and a $53.00 price target on the specialty pharmaceutical company’s stock. FBR & Co’s price objective points to a potential upside of 26.64% from the stock’s current price. FBR & Co also issued estimates for Supernus Pharmaceuticals’ Q3 2017 earnings at $0.28 EPS, Q4 2017 earnings at $0.25 EPS, FY2017 earnings at $1.05 EPS, Q1 2018 earnings at $0.27 EPS, Q2 2018 earnings at $0.42 EPS, Q3 2018 earnings at $0.48 EPS, Q4 2018 earnings at $0.53 EPS and FY2018 earnings at $1.70 EPS.

The analysts wrote, “We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions.””

A number of other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, July 5th. Piper Jaffray Companies reissued a “hold” rating and issued a $45.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Jefferies Group LLC lifted their price objective on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, June 28th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $47.00 price objective (up from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $48.38.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded down 1.76% during midday trading on Thursday, reaching $41.85. The company had a trading volume of 421,091 shares. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $50.04. The stock’s 50 day moving average is $42.84 and its 200 day moving average is $39.71. The company has a market capitalization of $2.12 billion, a PE ratio of 21.12 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities research analysts forecast that Supernus Pharmaceuticals will post $1.04 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Supernus Pharmaceuticals, Inc. (SUPN) Receives New Coverage from Analysts at FBR & Co” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/22/supernus-pharmaceuticals-inc-supn-receives-new-coverage-from-analysts-at-fbr-co.html.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 153,709 shares of company stock worth $7,223,108. Insiders own 6.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Pinebridge Investments L.P. grew its stake in shares of Supernus Pharmaceuticals by 1.3% during the second quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after buying an additional 86 shares during the last quarter. Louisiana State Employees Retirement System grew its stake in shares of Supernus Pharmaceuticals by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock worth $884,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Supernus Pharmaceuticals by 0.4% during the second quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after buying an additional 100 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Supernus Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after buying an additional 128 shares during the last quarter. Finally, CS Mckee LP grew its stake in shares of Supernus Pharmaceuticals by 0.5% during the second quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock worth $1,812,000 after buying an additional 200 shares during the last quarter. 95.36% of the stock is currently owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.